Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 2/20 | 0.45 |
| ▸ | PRTN3 | P24158 | 1/20 | 0.45 |
| ▸ | CTSL | P07711 | 4/20 | 0.45 |
| ▸ | CTSB | P07858 | 4/20 | 0.45 |
| ▸ | CTSS | P25774 | 3/20 | 0.45 |
| ▸ | CTSK | P43235 | 3/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | CA5A | P35218 | 1/20 | 0.43 |
| ▸ | CASP3 | P42574 | 1/20 | 0.43 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | PLAU | P00749 | 1/20 | 0.41 |
| ▸ | CTSD | P07339 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16645128 | 0.85 | CA2 (0.51) | ELANEPRTN3CTSLCTSBCTSS | |
| SCHEMBL2286310 | 0.76 | ELANE (0.41) | ELANEMEN1KMT2ALMNA | |
| SCHEMBL26816876 | 0.74 | MEN1 (0.58) | ELANEPRTN3CTSLCTSBCTSS | |
| SCHEMBL3731879 | 0.74 | CTSL (0.53) | ELANEPRTN3CTSLCTSBCTSS | |
| SCHEMBL28949078 | 0.74 | CTSL (0.57) | ELANEPRTN3CTSLCTSBCTSS | |
| SCHEMBL3733900 | 0.74 | CTSL (0.57) | ELANEPRTN3CTSLCTSBCTSS | |
| SCHEMBL3725467 | 0.74 | CTSL (0.57) | ELANEPRTN3CTSLCTSBCTSS | |
| SCHEMBL3727056 | 0.73 | CTSL (0.52) | ELANEPRTN3CTSLCTSBCTSS | |
| SCHEMBL1908598 | 0.73 | CTSK (0.62) | ELANEPRTN3CTSLCTSBCTSS | |
| SCHEMBL28892051 | 0.73 | TRPM8 (0.62) | ELANEPRTN3CTSLCTSBCTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230183326-A1 | PROTEIN-POLYMER-DRUG CONJUGATES | ASANA BIOSCIENCES, LLC | 2023-06-15 | — | — | US | disclosed |
| US-20190241649-A1 | PROTEIN-POLYMER-DRUG CONJUGATES | MERSANA THERAPEUTICS, INC. | 2019-08-08 | — | — | US | disclosed |
| US-9849191-B2 | Protein-polymer-drug conjugates | MERSANA THERAPEUTICS, INC. (US) | 2017-12-26 | — | — | US | disclosed |
| US-20150125474-A1 | PROTEIN-POLYMER-DRUG CONJUGATES | MERSANA THERAPEUTICS, INC. | 2015-05-07 | — | — | US | disclosed |
| US-20150104407-A1 | PROTEIN-POLYMER-DRUG CONJUGATES | MERSANA THERAPEUTICS, INC. | 2015-04-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150104407-A1 | PROTEIN-POLYMER-DRUG CONJUGATES | PBRM1, STAMBP, TSPO | ELANE 3558/4885PRTN3 225/4885CTSL 4230/4885 |
| US-20190241649-A1 | PROTEIN-POLYMER-DRUG CONJUGATES | PBRM1, STAMBP, TSPO | ELANE 3558/4885PRTN3 225/4885CTSL 4230/4885 |
| US-20230183326-A1 | PROTEIN-POLYMER-DRUG CONJUGATES | PBRM1, STAMBP, TSPO | ELANE 3558/4885PRTN3 225/4885CTSL 4230/4885 |
| US-20150125474-A1 | PROTEIN-POLYMER-DRUG CONJUGATES | PBRM1, STAMBP, TSPO | ELANE 3558/4885PRTN3 225/4885CTSL 4230/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.